Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // March 10th, 2010 // 7:24 am
A pleasant morning here on the Pharmalot corporate campus. After a recent spell of snow, spring appears to have finally bloomed. And that makes it a bit easier to cope with those mid-week deadlines and meetings, yes? So grab a cup of something stimulating and dig in for another day. Here are a few interesting items to help you on your way. Cheers, everyone…
Abbott Bests Biogen With Bid For Facet Biotech (Bloomberg)
Bristol-Myers’ CEO 2009 Pay Was Down 22 Percent (Associated Press)
Sandoz Names Don DeGolyer To Heads US Ops (Chain Drug Review)
Novartis Takes Option On Transgene Cancer Vaccine (Reuters)
Lilly, Amylin Diabetes Drug Await FDA OK (The Wall Street Journal)
Teva Pharmaceuticals Names Phillip Frost As Chairman (Associated Press)
Coffee pix thx to chichcacha flickr creative commons
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Abbott Laboratories, Amylin Pharmaceuticals, Biogen Idec, Bristol Myers Squibb, Byetta, Diabetes, Don DeGolyer, Eli Lilly, Executive Compensation, Executive Pay, Facet Biotech, Jim Cornelius, Novartis, Phillip Frost, Sandoz, Teva Pharmaceuticals, Transgene